TNFRSF17 and Miyoshi myopathy: Belantamab mafodotin (belamaf), a monomethyl auristatin F-conjugated anti-BCMA MoAb, was used as monotherapy in the DREAMM-2 clinical trial in patients with triple refractory MM [43].